Early Neuromuscular Blockade in Children with Pediatric Acute Respiratory Distress Syndrome

Abstract

Pediatric acute respiratory distress syndrome (PARDS) is a challenging problem with high mortality. Role of neuromuscular blockade in the management of ARDS to date has been controversial, and this study was done to study the role of neuromuscular blockade in children having PARDS and development of associated complications, if any. This was a prospective, case–control study conducted in the pediatric intensive care unit (PICU) of a tertiary care teaching hospital, over a period of 24 months. Patients of age 1 to 18 years who presented with or developed PARDS during their course of hospitalization were included after written informed consent was obtained from their parents and/or guardians. Patients with PARDS requiring invasive mechanical ventilation were partitioned into a case group and a control group. Case group patients were sedated and paralyzed using midazolam (1 µg/kg/min) and vecuronium (1 µg/kg/min), respectively, along with institution of definitive management. Control group patients were given definitive and supportive therapy, but no neuromuscular blocking agents (NMBAs). All patients were followed up for signs and symptoms of myopathy or neuropathy during the entire duration of hospital stay and up to 3 months after discharge. During the study period, 613 patients were admitted to the PICU of which 91 patients qualified as having PARDS. Sepsis was the main etiology in 67 of the 91 patients (73.6%) with PARDS. Fifty-nine patients were included in the study, of which 29 patients were included in the case group and 30 patients were included in the control group. Among the 29 case group patients, 25 patients (86.2%) were successfully extubated. Four patients from the case group expired, while 14 out of 30 control group patients (46.7%) expired. Hypotension was present in 26 case group patients (89.6%), of which all showed resolution within 48 hours of definitive treatment. The mean time to resolution of hypotension was 41.6 hours (standard deviation [SD]: 5.759; range: 24–48) for case group patients, significantly lower (p < 0.0001) than the mean time to resolution of 103 hours (SD: 18.995; range: 90–126) for the 10 control group patients with hypotension that survived. Mean oxygenation index (OI) following 48 hours of vecuronium therapy was significantly lower (p < 0.0001; 95% confidence interval: 5.9129–9.9671) than mean OI at admission for case group patients. None of the patients receiving vecuronium exhibited neuromuscular deficit during their hospital stay, at time of discharge, or at follow-up evaluation up to 3 months after discharge. In this study, pediatric cases diagnosed with PARDS and managed with mechanical ventilation and vecuronium therapy had improved mean OI following 48 hours of NMBA therapy and a lower mortality when compared with matched control group patients. Incidence of NMBA-related weakness was not commonly observed in these patients.

Keywords

PARDS - neuromuscular blocking agents - vecuronium

• References

• 1 Liu J, Wang W, Liu F, Li Z. Pediatric acute respiratory distress syndrome - current views. Exp Ther Med 2018; 15 (02) 1775-1780
• 2 Saharan S, Lodha R, Kabra SK. Management of acute lung injury/ARDS. Indian J Pediatr 2010; 77 (11) 1296-1302
• 3 Nanchal RS, Truwit JD. Recent advances in understanding and treating acute respiratory distress syndrome. F1000 Res 2018; 7: F1000 Faculty Rev-1322
• 4 Cheifetz IM. Pediatric ARDS. Respir Care 2017; 62 (06) 718-731
• 5 Cannon JW, Gutsche JT, Brodie D. Optimal strategies for severe acute respiratory distress syndrome. Crit Care Clin 2017; 33 (02) 259-275
• 6 Sharma BS, Meena HM, Garg V, Sharma P. Acute respiratory distress syndrome in children: recent perspective. Clin Res Pulmonol 2017; 5 (02) 1044
• 7 Wang J, Loh SW, Lee JH. Paediatric acute respiratory distress syndrome: progress over the past decade. J Crit Care Med 2018; (02) 24
• 8 Bourenne J, Hraiech S, Roch A, Gainnier M, Papazian L, Forel JM. Sedation and neuromuscular blocking agents in acute respiratory distress syndrome. Ann Transl Med 2017; 5 (14) 291
• 9 Arroliga A, Frutos-Vivar F, Hall J. , et al; International Mechanical Ventilation Study Group. Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest 2005; 128 (02) 496-506
• 10 Khemani RG, Smith LS, Zimmerman JJ, Erickson S. ; Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med 2015; 16 (05) (Suppl. 01) S23-S40
• 11 Shaikh Z, Pathak R. Revised Kuppuswamy and BG Prasad socio-economic scales for 2016. Int J Comm Pub Health 2017; 4 (04) 997-999
• 12 Messika J, Ben Ahmed K, Gaudry S. , et al. Use of high-flow nasal cannula oxygen therapy in subjects with ARDS: a 1-year observational study. Respir Care 2015; 60 (02) 162-169
• 13 Kumar SS, Selvarajan Chettiar KP, Nambiar R. Etiology and outcomes of ARDS in a resource limited urban tropical setting. J Natl Med Assoc 2018; 110 (04) 352-357
• 14 Fanelli V, Vlachou A, Ghannadian S, Simonetti U, Slutsky AS, Zhang H. Acute respiratory distress syndrome: new definition, current and future therapeutic options. J Thorac Dis 2013; 5 (03) 326-334
• 15 Westhoff M, Schönhofer B, Neumann P. , et al. [Noninvasive mechanical ventilation in acute respiratory failure]. Pneumologie 2015; 69 (12) 719-756
• 16 Barbosa MC, Barbosa AP, Rocco PR. Corticosteroids therapy in pediatric acute respiratory distress syndrome. Rev Bras Ter Intensiva 2010; 22 (04) 384-394
• 17 Grawe ES, Bennett S, Hurford WE. Early paralysis for the management of ARDS. Respir Care 2016; 61 (06) 830-838
• 18 Sottile PD, Albers D, Moss MM. Neuromuscular blockade is associated with the attenuation of biomarkers of epithelial and endothelial injury in patients with moderate-to-severe acute respiratory distress syndrome. Crit Care 2018; 22 (01) 63
• 19 Hraiech S, Yoshida T, Papazian L. Balancing neuromuscular blockade versus preserved muscle activity. Curr Opin Crit Care 2015; 21 (01) 26-33
• 20 Alhazzani W, Alshahrani M, Jaeschke R. , et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2013; 17 (02) R43
• 21 Yegneswaran B, Murugan R. Neuromuscular blockers and ARDS: thou shalt not breathe, move, or die!. Crit Care 2011; 15 (05) 311
• 22 Paramore S. Effects of the use of neuromuscular blocking agents on acute respiratory distress syndrome outcomes: a systematic review. J Am Assoc Nurse Pract 2018; 30 (06) 327-332
• 23 Annane D. What is the evidence for harm of neuromuscular blockade and corticosteroid use in the intensive care unit?. Semin Respir Crit Care Med 2016; 37 (01) 51-56
• 24 Bouju P, Tadié JM, Barbarot N. , et al. Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study. Ann Intensive Care 2017; 7 (01) 10
• 25 Groetzinger LM, Rivosecchi RM, Kane-Gill SL, Donahoe MP. Association between train-of-four values and gas exchange indices in moderate to severe acute respiratory distress syndrome. Ann Pharmacother 2016; 50 (12) 1009-1015
• 26 Sottile PD, Kiser TH, Burnham EL. , et al; Colorado Pulmonary Outcomes Research Group (CPOR). An observational study of the efficacy of cisatracurium compared with vecuronium in patients with or at risk for acute respiratory distress syndrome. Am J Respir Crit Care Med 2018; 197 (07) 897-904
• 27 Barmparas G, Dhillon NK, Tatum JM. , et al. Extended neuromuscular blockade in acute respiratory distress syndrome does not increase mortality. J Surg Res 2018; 231: 434-440
• 28 Wilsterman MEF, de Jager P, Blokpoel R. , et al. Short-term effects of neuromuscular blockade on global and regional lung mechanics, oxygenation and ventilation in pediatric acute hypoxemic respiratory failure. Ann Intensive Care 2016; 6 (01) 103